

**Fișă de verificare a îndeplinirii standardelor minimale  
(valabilă pentru obținerea atestatului de abilitare în Domeniul Medicină sau Domeniul Farmacie)**  
(în conformitate cu O.M. 6129/20.12.2016)

**Candidat\_CAINAP CALIN IOAN\_**

Nr. Crt.	Activi- tatea	Tipul activităților	Standarde minimale abilitare	Note asupra metodei de calcul	Gradul de îndeplinire
0	1	2	3	4	5
1.	Cercetare	a. Articole <i>in extenso</i> in reviste cotate ISI Thomson Reuters (articole în reviste cu factor de impact) în calitate de autor principal	minim 10 articole	<p>În analiză vor fi incluse articole <i>in extenso</i> originale și reviews. Autorul sau autorii principali ai unei publicații se consideră a fi oricare dintre următorii:</p> <ul style="list-style-type: none"> <li>a. Primul autor</li> <li>b. Autorul corespondent</li> <li>c. Alți autori, a căror contribuție este indicată explicit în cadrul publicației a fi egală cu contribuția primului autor sau a autorului corespondent</li> <li>d. Ultimul autor</li> </ul>	<p><b>DA</b></p> <p><b>1.</b>Chemotherapy – induced cardiotoxicity in oncology drugs involved and clinical assessment. Cainap SS, Nagy V, <b>Cainap C</b>.Farmacia 2016, 64(4):487-492 <b>IF=1.2</b></p> <p><b>2.</b>Results of third-generation epirubicin/cisplatin/xeloda adjuvant chemotherapy in patients with radically resected gastric cancer. <b>Cainap C</b>, Nagy V, Seicean A, Gherman A, Laszlo I, Lisencu C, Nadim AH, Constantin AM, Cainap S.J BUON. 2016 Mar-Apr;21(2):349-59. <b>IF=0.741</b></p> <p><b>3.</b>Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. <b>Cainap C</b>, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S. J Clin Oncol. 2015 Jan 10;33(2):172-9 <b>IF = 18.44</b></p> <p><b>4.</b>The Impact of miRNA in Colorectal Cancer Progression and Its Liver Metastases. Balacescu O, Sur D, <b>Cainap C</b>, Visan S, Cruceriu D, Manzat-Saplacan R, Muresan MS, Balacescu L, Lisencu C, Irimie A.Int J Mol Sci. 2018 Nov 22;19(12). pii: E3711. doi: 10.3390/ijms19123711. <b>IF= 3.878</b></p> <p><b>5.</b>Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. Sur D, Havasi A, <b>Cainap C</b>, Samasca G, Burz C, Balacescu O, Lupan I, Deleanu D, Alexandru Irimie. J Clin Med. 2020 Jan 9;9(1). Pii: E182. Doi: 0.3390/jcm9010182 <b>IF = 5.688</b></p> <p><b>6.</b>Skeletal Muscle Metastasis in Papillary Thyroid Microcarcinoma Evaluated by F18-FDG PET/CT. Hitu L, <b>Cainap C</b>, Apostu D, Gabora K, Bonci EA, Badan M, Mester A, Piciu A.Diagnostics 2020, 10, 100. <b>IF= 2.489</b></p> <p><b>7.</b> The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia. Maniu DR, Blag C, Popa G, Bota M, Vlad C, <b>Cainap C</b>, Balacescu O, Pop L,</p>

			<p>Cainap SS. J BUON. 2018 Dec;23(7):122-131. <b>IF=1,379</b></p> <p><b>8.</b> Gastric cancer: adjuvant chemotherapy versus chemoradiation. A clinical point of view. Cainap C, Vlad C, Seicean A, Balacescu O, Seicean R, Constantin AM, Balacescu L, Crisan O, Marta MM, Cainap S. J BUON. 2019 Nov-Dec;24(6):2209-2219. <b>IF= 1,379</b></p> <p><b>9.</b> Platinum derivatives: a multidisciplinary approach. Gheorghe-Cetean S, Cainap C, Oprean L, Hangan A, Virag P, Fischer-Fodor E, Gherman A, Cainap S, Constantin AM, Laszlo I, Vlad C, Oprean R. J BUON. 2017 May-Jun;22(3):568-577. <b>IF= 1,344</b></p> <p><b>10.</b> The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type KRAS metastatic colorectal cancer. Is it really the next best thing in miRNAs? Daniel Sur, Calin Cainap , Claudia Burz , Andrei Havasi , Irina Camelia Chis , Catalin Vlad , Vladan Milosevic , Ovidiu Balacescu , Alexandru Irimie J BUON. 2019 Dec;24(5):122-131. <b>IF=1,379</b></p>
	<b>b. (ISI) Factor cumulat de Impact autor principal (FCIAP)</b>	minim 10	<p>O revistă cotată ISI este o revistă pentru care Thomson Reuters calculează și publică factorul de impact în „Journal Citation Reports”. Factorul cumulat de Impact va fi calculat pentru articolele la care candidatul este autor principal (FCIAP=suma factorilor de impact ai articolelor publicate de autor în calitate de autor principal în reviste cotate ISI)</p> <p style="text-align: right;"><b>37,86</b></p>
	<b>c. Articole in extenso in reviste cotate ISI Thomson Reuters în calitate de coautor</b>	minim 5 articole	<p>1. Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure Jabbour E, Chalhoub B, Suzan F, Aloulou S, Cainap C, Toumi N, Fermé C, Carde P, Ribrag V. Leuk Lymphoma. 2004 Jul;45(7):1391-4. <b>IF= 1,147</b></p> <p>2. Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases. Oprea C, Cainap C, Azoulay R, Assaf E, Jabbour E, Koscielny S, Lapusan S, Vanel D, Bosq J, Ribrag V. Br J Haematol. 2005 Nov;131(4):468-71 <b>IF= 4,08</b></p> <p>3. Spectroscopic and DFT study of atenolol and metoprolol and their copper complexes. Cozar O, Szabó L, Cozar IB, Leopold N, David L, Cainap C, Chis V. Journal of Molecular Structure 993 (2011) 357–366. <b>IF= 1,634</b></p> <p>4. Pain palliation by endoscopic ultrasound-guided celiac plexus neurolysis in patients with unresectable pancreatic cancer. Seicean A, Cainap C, Gulei I, Tantau M,</p>

			<p>Seicean R. J Gastrointestin Liver Dis. 2013 Mar;22(1):59-64. <b>IF= 1,84</b></p> <p><b>5.</b> Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer. O'Neil BH, Căinap C, Van Cutsem E, Gorunova V, Karapetis CS, Berlin J, Goldberg RM, Qin Q, Qian J, Ricker JL, Fischer J, McKee MD, Carlson DM, Kim TW. Clin Colorectal Cancer. 2014 Sep;13(3):156-163 <b>IF= 2,907</b></p> <p><b>6.</b> MiRNAs roles in the diagnosis, prognosis and treatment of colorectal cancer. Sur DG, Colceriu M, Sur G, Aldea C, Silaghi C, Samasca G, Lupan I, Căinap C, Burz C, Irimie A. Expert Rev Proteomics. 2019 Oct;16(10):851-856. doi: 10.1080/14789450.2019.1659732. <b>IF= 2,963</b></p> <p><b>7.</b> The in vivo modulatory effects of Cornus mas extract on photodynamic therapy in experimental tumors. Laszló IP, Laszló MR, Toma V, Baldea I, Olteanu D, David L, Moldovan B, Ion RM, Moldovan R, Filip GA, Kacso G, Cainap C, Clichici S, Muresan A. Photodiagnosis Photodyn Ther. 2020 Jan 8:101656. doi: 10.1016/j.pdpdt.2020.101656. <b>ISI = 2.589</b></p>
<b>d. Index Hirsch</b>	minim 6  <b>8</b>	Va fi luat în considerare Indexul Hirsch calculat utilizând ISI Web of Science, Core Collection, Thomson Reuters	<p>Web of Science</p> <p>Citation report for 29 results from Web of Science Core Collection between 2015 and 2018</p> <p>Total Publications: 29      h-index: 8      Average citations per item: 14.03</p> <p>Sum of Times Cited: 407      Citing articles: 402</p> <p>Without self citations: 401      Without self citations: 397</p>

Cluj – Napoca,

Semnătura,

6/04/2020